RNS Number : 3424E
Kromek Group PLC
24 November 2026

24 November 2026

Kromek Group plc
("Kromek" or the "Group")

International partnership expands biological threat detection capabilities

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that it has entered into a partnership with US-based Spectara to distribute its biological threat detection system in international markets.

The agreement, which excludes the United States and Japan, adds BioTOF z200, a commercially available MALDI-TOF mass spectrometry system to Kromek's biological detection portfolio, complementing its ongoing development of DNA sequencing technology.

BioTOF z200 is designed to identify known biological threats through automated collection and analysis of airborne samples either triggered or at pre-programmed intervals. It can operate for more than four weeks without human involvement, providing continuous monitoring supported by cloud-based data management and reporting.

Spectara reports that the system achieves a true identification rate of more than 99%, with zero false positives in testing involving more than 20 biological agents spanning spores, vegetative bacteria, virus, toxins and pharmaceutical based threats (e.g. fentanyl).

The system has achieved Technology Readiness Level 9 (TRL-9), the highest level of technology readiness, and has been designated under the US Department of Homeland Security's SAFETY Act. It is already deployed by the US Department of War.

The partnership will enable Kromek to offer customers two complementary approaches to biological threat detection. While MALDI-TOF provides rapid anomaly detection of potential threats, Kromek's DNA sequencing technology is being developed to deliver more detailed genomic analysis and identification, including the detection of previously unknown pathogens.

Dr Arnab Basu, CEO of Kromek Group, said: "BioTOF is an established technology with a strong track record, and its addition to our portfolio represents an important development for our biological detection business.

"Our work in DNA sequencing is aimed at providing a deeper understanding of both known and emerging biological threats, while BioTOF offers an existing capability for continuous monitoring and rapid identification.

"The agreement broadens the solutions we can offer customers and gives us an opportunity to develop our biological detection business in new international markets."

Wayne Bryden, CEO of Spectara, said: "Biodefense has reached an inflection point and governments around the world have taken notice of the potential harm associated with AI designed or enhanced biological threats. They are seeking innovative solutions to keep their citizens and soldiers safe. In Kromek we have found a partner with deep experience, huge global reach, and complementary technology. Our agreement gives us access to Kromek's large, international network and creates holistic

and affordable biodefense solutions capable of immediate results and deep interrogation. We are thrilled to be working together toward our common goal of bolstering global biodefense capabilities."

Kromek has been developing biological threat detection technology for several years, working with government agencies in the UK and United States, including the US Department of Homeland Security and the Defense Advanced Research Projects Agency (DARPA).

The Group has also established a specialist bioaerosol evaluation facility at its headquarters in Sedgefield, County Durham, to support the development and testing of biological detection systems.

For further information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://investors.kromek.com/link/P3MM6e
Kromek Group plc Arnab Basu, CEO Claire Burgess, CFO	+44 (0)1740 626 060
Cavendish Capital Markets Limited (Nominated Adviser and Broker) Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance Michael Johnson – Sales	+44 (0)20 7220 0500
Gracechurch Group (Financial PR) Harry Chathli/Claire Norbury	+44 (0)20 4582 3500

Engage with the Kromek management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our interactive investor hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAFFDADSKFAA